


BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

Date: 23.03.2026

**To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001**

Ref: Scrip Code: 531752 Scrip ID: BIOGEN

Dear Sir / Madam,

Sub: Outcome of the Board Meeting of the board held on 23rd March 2026

Ref: Regulations 30 other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Board recommends the issuance of fully paid-up Bonus Shares in the ratio of 1:6.


Pursuant to Second proviso to Regulation 30(6) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Monday 23rd March 2026 at the Registered Office of the Company and transacted the following major businesses:

- 1.) The Board has considered & approved Increasing the Authorized Share Capital of the Company from Rs. 91,00,00,000 to Rs 1,08,00,00,000 subject to the approval of the shareholders through Postal Ballot.
- 2.) The Board has Recommended alteration of Capital Clause (Clause V) in the Memorandum of Association of the Company, subject to the approval by shareholders through Postal Ballot.
- 3.) The Board of directors have approved and recommended the issuance of fully paid-up Bonus Shares in the ratio of 1:6 (i.e. 1 (one) fully paid-up equity share for every 6 (six) fully paid-up equity share held, subject to the shareholders' approval through Postal Ballot. (Annexure -A).

Registered Office Address: Shop No. 8, First Floor, Maker's – 1 Building, Jawahar Road, Rajkot-360001

E mail biogenpharmachem@gmail.com

BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

- 4.) The Board has considered and approved the Appointment of M/s. Goenka Mehta & Associates Chartered Accountants, Rajkot as the Statutory Auditors of the Company to fill the casual vacancy caused by the resignation due to significant medical conditions of M/s. Rishi Sekhri & Associates Chartered Accountants Mumbai subject to the approval by shareholders through Postal Ballot.
- 5.) The Board has Considered & approved the draft notice of Postal Ballot.
- 6.) The Board has Considered & approved the appointment of M/s Daxa Negi & Associates, Practicing Company Secretary to act as the Scrutinizer for conducting the entire process of Postal Ballot including remote e-voting process, in a fair and transparent manner.

The board meeting commented at **07:00 PM** and concluded at **07:30 PM**

Please take the above intimation in your records.


Thanking You.

**Yours Faithfully,
For, Biogen Pharmachem Industries Limited**

KELASH
BUNKAR

**Kelash Bunkar
Director**

BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

Information as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with respect to issue of bonus equity shares:

Type of securities to be issued	Equity Shares
Type of issuance	Bonus Issue
Total number of securities proposed to be issued (approximately)	15,04,33,833 equity shares of Rs. 1/- each.
Whether bonus is out of free reserves created out of profits or share premium account.	The Bonus equity shares will be issued out of Securities Premium available as on 31 st March, 2025
Bonus Ratio	1:6 i.e. 1 (one) fully paid-up equity share for every 6 (six) fully paid-up equity share of Rs. 1/- each held as on the date of record date. The record date will be announced in due course. The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights as the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared after the new equity shares are allotted.
Details of share capital - pre and post bonus issue	Pre-Bonus issue: Paid up equity share capital as on the date of this letter is Rs. 90,26,03,000/- consisting of 90,26,03,000 equity shares of Rs. 1/- each. Post bonus issue: Paid up equity share capital shall be Rs. 1,05,30,36,833/- consisting of 1,05,30,36,833 equity shares of RS.1/- each.
Free reserves and/ or share premium required for implementing the bonus for implementation of Bonus Issue.	Rs. 15,04,33,833/- will be utilised from Securities Premium for implementation of Bonus Issue.
Free reserves and/ or share premium available for capitalization and the date as on which such balance is available	Securities Premium available as on 31 st March, 2025 is Rs. 17,00,00,000/-
Whether the aforesaid figures are audited	Yes
Estimated date by which such bonus shares would be credited/dispatched	Within two months from the date of the Board approval.

KELASH
BUNKAR

By signing this document, the undersigned hereby certifies that the information furnished is true and correct to the best of his knowledge and belief and that the same is in accordance with the facts and circumstances.

Registered Office Address: Shop No. 8, First Floor, Maker's – 1 Building, Jawahar Road, Rajkot-360001

E mail biogenpharmachem@gmail.com